Control Bionics (ASX:CBL) EBIT : A$-5.86 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Control Bionics EBIT?

Control Bionics's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was A$-3.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-5.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Control Bionics's annualized ROC % for the quarter that ended in Jun. 2024 was -132.89%. Control Bionics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -373.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Control Bionics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -36.45%.

Control Bionics EBIT Historical Data

The historical data trend for Control Bionics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Control Bionics EBIT Chart

Control Bionics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT

-3.52

-6.09

-5.62

-5.86

Control Bionics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial			-2.97	-2.97	-2.65	-2.18	-3.68

Competitive Comparison of Control Bionics's EBIT

For the Medical Devices subindustry, Control Bionics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Control Bionics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Control Bionics's EV-to-EBIT falls into.

Control Bionics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.86 Mil.

Control Bionics (ASX:CBL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Control Bionics's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-8.718 * ( 1 - 0% )	/	( (6.642	+	6.479)	/ 2 )
=	-8.718	/	6.5605
=	-132.89 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.926	-	0.97	-	( 1.314	-	max(0, 1.152	-	3.846	+	1.314	))
=	6.642

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.027	-	1.567	-	( 0.981	-	max(0, 2.403	-	3.762	+	0.981	))
=	6.479

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Control Bionics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.366	/	( ( (0.966 + max(1.412, 0))	+	(1.219 + max(0.351, 0)) )	/	2 )
=	-7.366	/	( ( 2.378	+	1.57 )	/	2 )
=	-7.366	/	1.974
=	-373.15 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.907	+	0.518	+	0.107)	-	(0.97	+	0	+	0.15)
=	1.412

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.534	+	0.404	+	0.19)	-	(1.567	+	0	+	0.21)
=	0.351

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Control Bionics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-5.858	/	16.072
	=	-36.45 %

Control Bionics EBIT Related Terms

Thank you for viewing the detailed overview of Control Bionics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Control Bionics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Control Bionics Ltd (ASX:CBL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121

Website

https://www.controlbionics.com

Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically it derives a majority of revenue from North America and has its presence in Australia as well.